New in-office test may improve diagnosis of dry eye

BioLight Israeli Life Sciences announced that its multi-assay test for evaluating tear components has shown it can provide a more robust diagnostic output than other dry eye tests.

The company says TeaRx provides a simple, rapid, semi-quantitative and objective analysis of tear film constituents originating from different locations in the eye, potentially allowing for differentiation among various underlying etiologies.

In a prospective study, TeaRx demonstrated sensitivity of 86%, specificity of 87% and a positive predictive value of 87%.

"We are very excited about the results of this second U.S. clinical trial. TeaRx allows for an in-office, multi-assay testing process which, for the first time, has the potential of going beyond the binary diagnosis of dry eye disease by also identifying sub-populations among those who suffer from the syndrome. TeaRx also has the potential of becoming a valuable companion diagnosis tool to assist physicians in customizing treatment for DES patients. To those ends, these trial results will be used as a basis for discussion with global regulatory authorities, including the FDA, regarding the product approval process for this important test," said Suzana Nahum Zilberberg, CEO of BioLight.